In conclusion, our results suggest that RRM2 overexpression in renal cancer cells plays a key role in sunitinib resistance in patients with RCC and that RRM2 competes with UBE3A to bind to the C‐terminus of ANXA1, preventing ANXA1 degradation. Here, ANXA1 is linked to renal cell carcinoma.